1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

US judge sets hearing for Biogen vs Elan dispute over Tysabri

 
• By Nancy Faigen

A federal judge has agreed to give Biogen Idec expedited discovery relating to documents concerning an ongoing dispute with Elan. Elan is fighting a claim from Biogen Idec that its recent $1.5 billion deal with Johnson & Johnson placed it in material breach of the commercialisation pact for the multiple sclerosis drug Tysabri (natalizumab). A hearing, originally set for the end of August, has been moved to September 10th.

A federal judge has agreed to give Biogen Idec expedited discovery relating to documents concerning an ongoing dispute with Elan. Elan is fighting a claim from Biogen Idec that its recent $1.5 billion deal with Johnson & Johnson placed it in material breach of the commercialisation pact for the multiple sclerosis drug Tysabri (natalizumab). A hearing, originally set for the end of August, has been moved to September 10th.

The case is before Judge Deborah Batts of the US District Court for the Southern District of New York. Elan...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Vigil’s Iluzanebart Disappoints In Rare Neurodegenerative Disease

 
• By Jessica Merrill

The Phase II TREM2 agonist is not part of Sanofi’s planned acquisition.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

More from Therapeutic Category

New Regenxbio DMD Data Support Gene Therapy Accelerated Approval

 
• By Joseph Haas

Regenxbio reported functional and biomarker data from an ongoing study of RGX-202, which it hopes to file for approval in Duchenne muscular dystrophy in 2026.

A MoonLake Buyout Would Boost Merck & Co’s Immunology Ambitions

 
• By Andrew McConaghie

As the patent protection clock ticks down on Merck’s flagship blockbuster Keytruda, the company is reported to be pursuing the inflammation and immunology biotech. Such a move would bulk up its sparse I&I pipeline.

ASCO: Carvykti Data Raise Possibility Of Myeloma Cure

 
• By Alaric DeArment

J&J presented data at the American Society of Clinical Oncology meeting showing more than five-year disease- and therapy-free survival, but a myeloma working group will need to define what makes a cure.